Injective (INJ) is currently priced at $3.07, reflecting a 24-hour change of 1.33%. The asset has shown resilience with a daily trading range of $2.96 to $3.08, indicating strong price action within this span.

The trading volume stands at approximately 44.28 million, translating to a volume-to-market cap ratio of 14.42%. This level of volume suggests a healthy trading interest, particularly as the 1-hour RSI indicates strong bullish momentum at 77, suggesting the asset may be overbought in the short term.

Analyzing moving averages, the 8-period SMA is at $3.02 (+1.81%), while the 13-period SMA is slightly lower at $3.01 (+2.10%). The consistent upward trend in the short-term moving averages illustrates positive price momentum, supported by the 7-day RSI of 53, which indicates a neutral trend, suggesting room for growth without immediate overextension.

In the past 14 days, Injective has gained 4.37%, while the 30-day change indicates a slight decline of 3.51%. This short-term bullish trajectory contrasts with the longer-term perspective, indicating potential volatility as the market digests recent gains.

The all-time high of $52.62 remains significantly distant, suggesting substantial upside potential for investors willing to hold through market fluctuations. The current price shows a promising technical setup, particularly with the immediate bullish indicators from moving averages and RSI readings.

Based on this analysis, I recommend a Buy rating for Injective (INJ). The combination of positive short-term momentum, healthy trading volume, and favorable moving average alignments suggests a strong potential for upward movement, provided market conditions remain stable.